These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 23256101

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
    O'Connor AB, Noyes K, Holloway RG.
    Pharmacoeconomics; 2008; 26(12):1045-64. PubMed ID: 19014205
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
    Forde G.
    J Fam Pract; 2007 Feb; 56(2 Suppl Pain):3-12. PubMed ID: 17270113
    [No Abstract] [Full Text] [Related]

  • 6. [DRUG THERAPY OF NEUROPATHIC PAIN BASED ON THE LATEST RECOMMENDATIONS].
    Kiss G.
    Ideggyogy Sz; 2015 Mar 30; 68(3-4):93-8. PubMed ID: 26434196
    [Abstract] [Full Text] [Related]

  • 7. [Evidence-based pharmacotherapy of neuropathic pain syndromes].
    Braune S.
    MMW Fortschr Med; 2004 Dec 09; 146(50):49-51. PubMed ID: 15658522
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Drugs for neuropathic pain.
    Kalso E, Aldington DJ, Moore RA.
    BMJ; 2013 Dec 19; 347():f7339. PubMed ID: 24355386
    [No Abstract] [Full Text] [Related]

  • 10. Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
    Dosenovic S, Jelicic Kadic A, Miljanovic M, Biocic M, Boric K, Cavar M, Markovina N, Vucic K, Puljak L.
    Anesth Analg; 2017 Aug 19; 125(2):643-652. PubMed ID: 28731977
    [Abstract] [Full Text] [Related]

  • 11. Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.
    Ziegler D, Schneider E, Boess FG, Berggren L, Birklein F.
    J Diabetes Complications; 2014 Aug 19; 28(5):698-704. PubMed ID: 24862108
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Review of current guidelines on the care of postherpetic neuralgia.
    Argoff CE.
    Postgrad Med; 2011 Sep 19; 123(5):134-42. PubMed ID: 21904096
    [Abstract] [Full Text] [Related]

  • 18. Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients.
    Ruessmann HJ, German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch tätiger Arzte e.V.).
    J Diabetes Complications; 2009 Sep 19; 23(3):174-7. PubMed ID: 18403218
    [Abstract] [Full Text] [Related]

  • 19. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
    Tanenberg RJ, Irving GA, Risser RC, Ahl J, Robinson MJ, Skljarevski V, Malcolm SK.
    Mayo Clin Proc; 2011 Jul 19; 86(7):615-26. PubMed ID: 21719618
    [Abstract] [Full Text] [Related]

  • 20. Objective evidence for the reversibility of nerve injury in diabetic neuropathic cachexia.
    Grewal J, Bril V, Lewis GF, Perkins BA.
    Diabetes Care; 2006 Feb 19; 29(2):473-4. PubMed ID: 16443922
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.